OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← British Nuclear Medicine Society

2024-12-31-accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales) REGISTERED CHARITY NUMBER: 1150234

REPORT OF THE TRUSTEES AND

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

BRITISH NUCLEAR MEDICINE SOCIETY

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

Page
Report of the Trustees 1 to 4
Independent Examiner's Report 5
Statement of Financial Activities 6
Balance Sheet 7
Cash Flow Statement 8
Notes to the Cash Flow Statement 9
Notes to the Financial Statements 10 to 15
Detailed Statement of Financial Activities 16 to 17

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to raising the profile of nuclear medicine and to promote the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

Page 1

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES Our committees

Professional Standards Committee

The Professional Standards Committee advises the Officers and Council of BNMS on the development and implementation on professional standards and audit. They develop, promote, publicise and review guidelines for the delivery of nuclear medicine services and procedures and are also responsible for developing patient information in nuclear medicine.

Scientific and Education Committee

The British Nuclear Medicine Society (BNMS) established the combined Scientific Committee and Education Committee in 2016.

The mandate of the Scientific and Education Committee is to develop an education and scientific programme, nominate invited speakers and the chairs of sessions.

The remit of this committee is to provide resources and encourage the provision of education and training to support Continuing Professional Development/Continuous Medical Education and work towards revalidation. The Education Committee is Multidisciplinary, consisting of Nuclear Medicine Physicians, Clinical Practioners, Physicists, Nurses and Radiopharmacists.

Research & Innovation Committee

Research & Innovation Committee (RIC) reports to BNMS council and governs BNMS Research Champions network and links to the MRT Research Committee.

The purpose of the RIC is to provide integrated clinical, scientific and operational leadership and management/oversight of delivery of the BNMS Research Strategy.

The roles of the Research & Innovation Committee are to develop and deliver BNMS Research Strategy with aims: 1. To enhance radionuclide research delivery in the United Kingdom leading to service improvement and better care of patients. To accomplish this the BNMS will outline research priority areas highlighting current unmet needs. It will investigate through research sessions and workshops on-line and at face-to-face meetings on how best its multi professional membership can develop projects and achieve funding from the appropriate bodies. The BNMS will facilitate research networks through the BNMS website and offer peer support and review through face-to-face meetings at the BNMS conferences. It will endeavour to contribute to and work with the professional bodies involved in research, the UK Colleges, the charities, and the national and international Nuclear Medicine societies. It will foster links with research partners including the UK PET Network the CRUK Radiation Network, RadNet, the National Cancer Imaging Translational Accelerator (NCITA) and Industry Academic partnership via Industry forum held 2-3 times a year.

  1. To build up an evidence base for new radionuclide molecular diagnostic and therapeutic procedures. The BNMS research network group is developing a data base of current research in the UK and a data base of available research funding. It is also developing a data base to ethically collect data from ongoing research studies.

UK MRT Consortium

The UK molecular radiotherapy consortium is a group comprised of both healthcare professionals and patient advocates who are directly and passionately associated in delivering and caring for patients undergoing molecular radiotherapy based treatments.

The UK MRT Consortium are the first organisation to serve current and future patients who may find the need to receive such types of treatment to help maintain and sustain both quality and duration of life.

By bringing members and fellows of both the British Nuclear Medicine Society and the Royal College of Radiologists together along with patient advocates and nationally recognised charities, we will endeavour to ensure that all parts of the United Kingdom will have equitable access to current and future therapies, raise public awareness of such treatments, design and encourage activity in nationally recognised molecular radiotherapy trials.

Trainee Committee

Aims of BNMS Medical Trainee Committee

Increase awareness of diagnostic and therapeutic Nuclear Medicine amongst doctors-in-training and medical students. Provide educational content for doctors-in-training and medical students to aid their understanding of working in Nuclear Medicine and the training pathways.

Provide opportunities for doctors-in -training and medical students to engage with the BNMS and improve their application for the specialties/training numbers.

Radiographers Technologists and Nurses

The BNMS Radiographers, Technologists & Nurses' Committee:-

Page 2

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES

Objectives

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

Income
Commercial exhibition income
Annual conference delegate registration fees
Less: Scientific meeting expenses
Surplus		 Spring
Belfast
£
202,375
112,809
315,184
261,309
53,874		 Autumn
Norwich
£
18,336
13,840
32,177
21,523
10,653		 Online
Educational
£
5,008
8,366
13,374
12,966
408		 Total
£
225,718
135,015
360,734
295,799
64,935

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain general reserve levels at the equivalent of at least 18 months expenditure. The unrestricted fund balance (excluding designated funds) at the year end of £466,821 is above this level and continues to be carefully monitored by the trustees.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians 11 St Andrews Place Regents Park London NW1 4LE

Page 3

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees

Who are also directors Mrs J Croasdale Dr R Graham (resigned 13 May 2024) Dr S Redman (resigned 20 May 2025) Mr C S Kalirai Mrs S Dizdarevic (appointed 13 May 2024)

Radiopharmacist Radiologist Radiologist Clinical Scientist Professor

Independent Examiner

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

Approved by order of the board of trustees on 8 May 2025 and signed on its behalf by:

Mr C S Kalirai - Trustee

Page 4

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

8 May 2025

Page 5

BRITISH NUCLEAR MEDICINE SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2024

Unrestricted
Restricted
fund
fund
Notes
£
£
INCOME AND ENDOWMENTS FROM
Donations and legacies
2
-
-
Other trading activities
3
441,142
-
Investment income
4
9,414
207
Other income
75,454
-
Total
526,010
207
EXPENDITURE ON
Raising funds
5
542,381
-
NET INCOME/(EXPENDITURE)
(16,371)
207
RECONCILIATION OF FUNDS
Total funds brought forward
481,883
14,273
TOTAL FUNDS CARRIED FORWARD
465,512
14,480		 2024
Total
funds
£
-
441,142
9,621
75,454
526,217
542,381
(16,164)
496,156
479,992		 2023
Total
funds
£
4,400
412,766
5,933
90,564
513,663
422,297
91,366
404,790
496,156

The notes form part of these financial statements

Page 6

BRITISH NUCLEAR MEDICINE SOCIETY

BALANCE SHEET 31 DECEMBER 2024

Unrestricted
Restricted
fund
fund
Notes
£
£
FIXED ASSETS
Tangible assets
11
1,644
-
CURRENT ASSETS
Debtors
12
243,023
-
Cash at bank
405,521
14,480
648,544
14,480
CREDITORS
Amounts falling due within one year
13
(184,676)
-
NET CURRENT ASSETS
463,868
14,480
TOTAL ASSETS LESS CURRENT LIABILITIES
465,512
14,480
NET ASSETS
465,512
14,480
FUNDS
14
Unrestricted funds
Restricted funds
TOTAL FUNDS		 2024
Total
funds
£
1,644
243,023
420,001
663,024
(184,676)
478,348
479,992
479,992
465,512
14,480
479,992		 2023
Total
funds
£
2,415
168,525
433,145
601,670
(107,929)
493,741
496,156
496,156
481,883
14,273
496,156

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2025 and were signed on its behalf by:

Mr C S Kalirai - Trustee

The notes form part of these financial statements

Page 7

BRITISH NUCLEAR MEDICINE SOCIETY

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

Notes
Cash flows from operating activities
Cash generated from operations
1
Net cash (used in)/provided by operating activities
Cash flows from investing activities
Purchase of tangible fixed assets
Interest received
Net cash provided by investing activities
Change in cash and cash equivalents in
the reporting period
Cash and cash equivalents at the
beginning of the reporting period
Cash and cash equivalents at the end of
the reporting period		 2024
£
(22,766)
(22,766)
1
9,621
9,622
(13,144)
433,145
420,001		 2023
£
80,923
80,923
(433)
5,933
5,500
86,423
346,722
433,145

The notes form part of these financial statements

Page 8

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

Net (expenditure)/income for the reporting period (as per the
Statement of Financial Activities)
Adjustments for:
Depreciation charges
Interest received
(Increase)/decrease in debtors
Increase/(decrease) in creditors
Net cash (used in)/provided by operations		 2024
£
(16,164)
770
(9,621)
(74,498)
76,747
(22,766)		 2023
£
91,366
1,147
(5,933)
20,748
(26,405)
80,923

2.

ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.24 Cash flow At 31.12.24
£ £ £
Net cash
Cash at bank 433,145 (13,144) 420,001
433,145 (13,144) 420,001
Total 433,145 (13,144) 420,001

The notes form part of these financial statements

Page 9

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 15% on reducing balance Computer equipment - 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available of use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Page 10

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

2. DONATIONS AND LEGACIES

Donations
3.
OTHER TRADING ACTIVITIES
Commercial exhibition income
Annual conference delegate registration fees
Commission received
Royalties received
Other project income
4.
INVESTMENT INCOME
Deposit account interest
5.
RAISING FUNDS
Raising donations and legacies
Support costs
Other trading activities
Purchases
Awards and prizes
Journal subscriptions
Support costs
Aggregate amounts
6.
SUPPORT COSTS
Management
£
Raising donations and
legacies
121,015
Other trading activities
32,944
153,959		 Finance
£
-
3,578
3,578		 2024
£
-
2024
£
225,718
135,015
1,288
75,835
3,286
441,142
2024
£
9,621
2024
£
121,255
2024
£
300,138
2,748
74,029
44,211
421,126
542,381
Governance
Other
costs
£
£
-
240
770
6,919
770
7,159		 2023
£
4,400
2023
£
187,021
148,480
4,124
71,861
1,280
412,766
2023
£
5,933
2023
£
141,820
2023
£
239,557
1,432
39,488
-
280,477
422,297
Totals
£
121,255
44,211
165,466

Page 11

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

7. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

2024 2023
£ £
Other assurance services 5,360 3,831
Depreciation - owned assets 771 1,146

8. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Trustees' expenses

Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings.

9. STAFF COSTS

Wages and salaries
Other pension costs
The average monthly number of employees during the year was as follows:
Administrative		 2024
£
117,999
3,016
121,015
2024
3		 2023
£
86,558
3,079
89,637
2023
3

No employees received emoluments in excess of £60,000.

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

Unrestricted
Restricted
fund
fund
£
£
INCOME AND ENDOWMENTS FROM
Donations and legacies
4,400
-
Other trading activities
412,849
(83)
Investment income
5,768
165
Other income
90,564
-
Total
513,581
82
EXPENDITURE ON
Raising funds
422,080
217
NET INCOME/(EXPENDITURE)
91,501
(135)
RECONCILIATION OF FUNDS
Total funds brought forward
390,382
14,408
TOTAL FUNDS CARRIED FORWARD
481,883
14,273		 Total
funds
£
4,400
412,766
5,933
90,564
513,663
422,297
91,366
404,790
496,156

Page 12

continued...

Page 12 continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

11. TANGIBLE FIXED ASSETS

COST
At 1 January 2024 and 31 December 2024
DEPRECIATION
At 1 January 2024
Charge for year
At 31 December 2024
NET BOOK VALUE
At 31 December 2024
At 31 December 2023
12.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Other debtors
VAT
Prepayments and accrued income
13.
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade creditors
Social security and other taxes
VAT
Other creditors
Accrued expenses
14.
MOVEMENT IN FUNDS
Unrestricted funds
General fund
Restricted funds
Ross Breen Fund
TOTAL FUNDS		 Fixtures
and
Computer
fittings
equipment
Totals
£
£
£
905
30,534
31,439
718
28,306
29,024
28
743
771
746
29,049
29,795
159
1,485
1,644
187
2,228
2,415
2024
2023
£
£
76,022
49,542
73,955
39,132
10,541
-
82,505
79,851
243,023
168,525
2024
2023
£
£
59,558
4,160
2,539
1,959
-
13,989
116,877
82,440
5,702
5,381
184,676
107,929
Net
movement
At
At 1.1.24
in funds
31.12.24
£
£
£
481,883
(16,371)
465,512
14,273
207
14,480
496,156
(16,164)
479,992

Page 13

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

Unrestricted funds
General fund
Restricted funds
Ross Breen Fund
TOTAL FUNDS		 Incoming
Resources
Movement
resources
expended
in funds
£
£
£
526,010
(542,381)
(16,371)
207
-
207
526,217
(542,381)
(16,164)

Comparatives for movement in funds

Unrestricted funds
General fund
Restricted funds
Ross Breen Fund
TOTAL FUNDS		 Net
movement
At
At 1.1.23
in funds
31.12.23
£
£
£
390,382
91,501
481,883
14,408
(135)
14,273
404,790
91,366
496,156

Comparative net movement in funds, included in the above are as follows:

Unrestricted funds
General fund
Restricted funds
Ross Breen Fund
TOTAL FUNDS		 Incoming
Resources
Movement
resources
expended
in funds
£
£
£
513,581
(422,080)
91,501
82
(217)
(135)
513,663
(422,297)
91,366

A current year 12 months and prior year 12 months combined position is as follows:

Unrestricted funds
General fund
Restricted funds
Ross Breen Fund
TOTAL FUNDS		 Net
movement
At
At 1.1.23
in funds
31.12.24
£
£
£
390,382
75,130
465,512
14,408
72
14,480
404,790
75,202
479,992

Page 14

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

14. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 1,039,591 (964,461) 75,130
Restricted funds
Ross Breen Fund 289 (217) 72
TOTAL FUNDS 1,039,880 (964,678) 75,202

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2024.

Page 15

BRITISH NUCLEAR MEDICINE SOCIETY

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2024

INCOME AND ENDOWMENTS
Donations and legacies
Donations
Other trading activities
Commercial exhibition income
Annual conference delegate registration fees
Commission received
Royalties received
Other project income
Investment income
Deposit account interest
Other income
Members subscriptions
Total incoming resources
EXPENDITURE
Other trading activities
Scientific meeting expenses
Other project expenses
Awards and prizes
Journal subscriptions
Support costs
Management
Wages and social security
Pensions
Rent
Insurance
Subscriptions
Telephone
Postage and stationery
General meeting and travelling expenses
Sundries
Computer costs
Finance
Bank charges
Card charges
Direct debit processing costs
Other
Fixtures and fittings
Carried forward		 2024
£
-
225,718
135,015
1,288
75,835
3,286
441,142
9,621
75,454
526,217
295,799
4,339
2,748
74,029
376,915
117,999
3,016
1,312
1,112
2,080
681
658
13,907
247
12,947
153,959
1,646
446
1,486
3,578
28
28		 2023
£
4,400
187,021
148,480
4,124
71,861
1,280
412,766
5,933
90,564
513,663
238,607
950
1,432
39,488
280,477
86,558
3,079
1,280
1,033
678
709
867
19,711
355
19,398
133,668
1,681
-
1,253
2,934
33
33

This page does not form part of the statutory financial statements

Page 16

BRITISH NUCLEAR MEDICINE SOCIETY

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2024

Other
Brought forward
Computer equipment
Governance costs
Auditors' remuneration for non audit work
Payroll costs
Professional fees
Bookkeeping
Total resources expended
Net (expenditure)/income		 2024
£
28
742
770
5,360
240
250
1,309
7,159
542,381
(16,164)		 2023
£
33
1,114
1,147
3,831
240
-
-
4,071
422,297
91,366

This page does not form part of the statutory financial statements

Page 17